Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Up-front HSCT in Elderly AML
NCT03902665Phase 2Completed
- Sponsor
- Policlinico Gemelli
- Start
- Mar 2019
- Primary completion
- Mar 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic hematopoietic stem cells in acute myeloid leukemia (AML), sponsored by Policlinico Gemelli. Primary endpoint: Complete Remission Rate. Started Mar 2019; status: completed.
02
Drugs
allogeneic hematopoietic stem cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03902665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03902665.